Newsroom :: CytoDyn Inc. (CYDY)

For the latest results and updates on our Phase 2 CRC trial and more, here’s a direct link to our October 19, 2026 Investor Update Webinar

Learn More

CytoDyn to Present at the LD Micro Invitational XVI

May 15, 2026 8:30am EDT

Press Release

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

Apr 27, 2026 8:30am EDT

Press Release

CytoDyn to Host Investor Webcast

Apr 23, 2026 8:30am EDT

Press Release

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

Apr 22, 2026 8:30am EDT

Press Release

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

Apr 21, 2026 4:10pm EDT

Press Release

CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026

Apr 20, 2026 8:30am EDT

Press Release

CytoDyn to Present at the AACR Annual Meeting 2026

Apr 14, 2026 8:30am EDT

Press Release

CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer

Mar 24, 2026 8:30am EDT

Press Release

CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

Mar 05, 2026 8:30am EST

Press Release

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

Feb 20, 2026 8:30am EST

Press Release

1
2
3
4
5
6
7
8
9